We did not observe frequent new mutations in the BRAF gene itself correlating with resistance, consistent with the reported stability of the BRAF mutation in melanoma [34]; unlike the situation with other kinases such as BCR-ABL or epidermal growth factor receptor (EGFR), where resistance is often mediated by acquisition of additional mutations within the same gene. The gene discussed is BRAF; the disease is melanoma.